Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest tumour Stories

2011-09-30 08:21:00

MELBOURNE, Australia, Sept. 30, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer. VGX-100 is a human antibody...

2011-08-16 21:03:34

A study conducted by VHIO researchers confirms that a lack of vitamin D increases the aggressiveness of colon cancer The indication that vitamin D and its derivatives have a protective effect against various types of cancer is not new. In the field of colon cancer, numerous experimental and epidemiological studies show that vitamin D3 (or cholecalciferol) and some of its derivatives inhibit the growth of cancerous cells. Researchers at the Vall d'Hebron Institute of Oncology (VHIO), in...

2011-06-10 13:34:26

Surgeon Naia Uribe-Etxebarria has used a radioactive substance which, injected into a lung tumour, enables the detection of the path that the carcinoma intends to take in order to propagate itself. Concretely she applied technetium 99 in resectable non-small cell lung cancers (NSCLC) at an early stage (I or II), and in an intraoperative manner. Thanks to this, she detected with precision the sentinel node (SNOL); the primary node or ganglion of cells to receive lymphatic drainage from the...

2011-06-06 11:53:00

OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc. ("ImaginAb"), a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the...

2011-05-19 22:55:59

Researchers at the University of Oxford have developed a cheap and reliable diagnostic test for a rare form of cancer. The test involves screening tumour samples for a particular molecular fingerprint unique to this type of cancer. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumours in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to...

2011-04-18 14:31:37

Cancer researchers at the University of Calgary are investigating a new tool to use for the prognosis of breast cancer in patients. This new digital tool will help give patients a more accurate assessment of how abnormal and aggressive their cancer is and help doctors recommend the best treatment options. Currently, a useful factor for deciding the best treatment strategy for early-stage breast cancer is tumour grade, a score assigned by a pathologist based on how abnormal cancer cells from a...

2011-04-11 17:03:17

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer. The team "“ including researchers from the University of Hull and ETH Zurich "“ linked light-sensitive molecules with antibodies that target tumour blood vessels. When irradiated with light, the molecules create particles known as reactive oxygen species, which in high numbers...

2011-04-06 06:30:00

MELBOURNE, Australia, April 6, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5. IMC-3C5 is a fully-human IgG1 monoclonal antibody being developed by ImClone as a treatment for cancer. ImClone has exclusive rights from Circadian's 100%-owned subsidiary Vegenics to...

2011-04-06 06:30:00

MELBOURNE, Australia , April 6, 2011 /PRNewswire/ -- Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, ovarian and prostate cancers. VGX-100 improves the efficacy of Avastin® in a lung cancer model and further inhibits tumour growth when combined with Avastin® plus docetaxel in mouse models of human lung and ovarian cancer. Data expand on previous anti-cancer effects seen with VGX-100 in prostate, pancreatic...

2011-04-04 05:05:00

CRAIGAVON, Northern Ireland, April 4, 2011 /PRNewswire/ -- - Scientists at Almac and Queen's University Belfast Discover Novel Approach to Treat Cancer Patients New Study findings published in Clinical Cancer Research - The Journal of the American Association of Cancer Research (AACR) Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a...